Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Realgar-Indigo naturalis formula versus intravenous arsenic trioxide for newly diagnosed acute promyelocytic leukemia
ChiCTR-TRC-12002151Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2007
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Compound Huangdai Tablet and arsenic trioxide in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: complete remission, disease-free survival and 1 more. Started Nov 2007; status: completed.
02
Drugs
Compound Huangdai Tabletarsenic trioxide
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-TRC-12002151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002151.